BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene. Seelos is constructing a bimodular viral system harboring an endogenous alpha-synuclein (α-synu

Brain Scientific Inc., a medical device and technology company offering products and solutions related to the brain including neurology, AI and machine learning, has enhanced its disposable EEG headset, NeuroCapTM, with new features.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Jefferies Virtual Healthcare Conference. Presentation Details: Event: Jefferies Virtual Healthcare Conference Date: Thursda

Dr. Tina Cheng Committed to Research Innovation That Helps Patients, Family and Community Health [28-May-2020] CINCINNATI , May 28, 2020 /PRNewswire/ -- Tina L. Cheng , MD, MPH, will be the new chair of the Department of Pediatrics at the University of Cincinnati College of Medicine , the new chief medical officer at Cincinnati Children’s Hospital Medical Center

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT. A live webcast of the presentation will be available on the investors section of the Company’s website at www.v

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 1:00 p.m. ET. A live webcast of the session will be accessib

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis Four hundred students from Massachusetts and North Carolina are enrolling in this no-fee program that also provides students with computers and other technology resources The initiative builds upon Biogen’s Community Lab, which has enrolled more than 55,000 students to date, and the Lemelso

MacroGenics, Inc. announced that during the recent mid-cycle communication with the U.S. Food and Drug Administration, the FDA notified the Company that it is no longer planning to hold an Oncologic Drugs Advisory Committee meeting to discuss the Biologics License Application for margetuximab.

ReWalk Robotics Ltd. announced its financial results for the three months ended March 31, 2020.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation Goldman Sachs 41st Annual Global Healthcare Conference – June 9-11, 2020